Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Professor Anna Schuh awarded funding from the NIHR RIGHT programme

The NIHR has invested £34 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries (LMICs).

The NIHR Research and Innovation for Global Health Transformation (RIGHT) programme has awarded Official Development Assistance (ODA) funding to eight projects led by teams made up of researchers in the UK and those in LMICs.

Professor Anna Schuh from the Department of Oncology is leading one of the eight projects, and will be investigating two new techniques to diagnose Epstein-Barr virus, a common cause of blood cancers in sub-Saharan Africa. Her research in Tanzania and Uganda aims to speed up diagnosis and treatment of the infection, reducing the mortality rate from these cancers.

 

For more information on the full recipients of funding for this programme grant, please go to https://www.nihr.ac.uk/news/nihr-invests-34-million-into-global-health-research-on-epilepsy-infection-related-cancers-and-severe-stigmatising-skin-diseases/22764

Similar stories

New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes

A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.

Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Machine Learning Enhances Detection of Multiple Cancer Types from Blood

Researchers from the University of Oxford have developed TriOx, a highly sensitive blood test that detects six cancers at their earliest stages. Published today in Nature Communications, the findings highlight the test’s potential to transform early cancer detection and improve patient outcomes.

MSc Medical Physics with Radiobiology receives IPEM accreditation

The Department of Oncology at the University of Oxford is delighted to announce that our new MSc Medical Physics with Radiobiology programme has received Masters Level Accreditation from the Institute of Physics and Engineering Medicine (IPEM).

Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer

The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper “Goblet Cell Differentiation Subgroups in Colorectal Cancer.” This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).